Published Date: 02 Mar 2023
Registry data support an overall survival benefit of adding CDK4/6 inhibitors to hormone therapy in HR-positive metastatic breast cancer.
Read Full News1.
An ancient signaling pathway and 20 years of research offer hope for rare cancer
2.
Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus
3.
Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
Prostate cancer detection with PET CT and PET MRI is comparable.
1.
Cutting-Edge Cancer Care: The Precision Revolution in Surgical Oncology
2.
Decoding the Padua Score to Prevent Blood Clots in High-Risk Patients
3.
Exploring The Causes and Consequences of Low Transferrin Saturation
4.
Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation
5.
Living with Shwachman-Diamond Syndrome: A Journey of Hope and Strength
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation